Crystallization technologies are bridges between drug substances (DS) and drug products (DP) enabling consistent and robust safety and efficacy profiles of small molecule based medicines.

Controlled crystallization of an API in submicron size was enabled based on an accurate solubility profile and a growth inhibition property via semi-continuous processing, to meet special formulation requirements.

Diverse crystallization challenges encountered by CfPC (Center for Pharma Crystallization) and our clients will be analyzed systematically to provide insights into main bottleneck problems in today’s drug development programs.

Direct compression (DC) process is the preferred method for tablet production because it is both simple and energy saving.

Research studies show that the majority of API candidates in the development pipeline have a BCS Class II rating, which means those APIs need a solubilization strategy to promote the bioavailability to improve their chance of clinical success.

With the ability to develop both Drug Substance (DS) and Drug product (DP) under the same umbrella, our team enjoys a synergism absent in most CROs. The ability to bridge the DS/DP interface is a major competitive advantage, and we are able to shorten development timeline and to improve ruggedness of the DP process.

See how the Center for Pharma Crystallization (CfPC) at J-Star Research is effectively supporting new drug development programs.

Rational selection of solvents plays a critical role in solid form screening and production. On the one hand, a variety of solvents with different properties are chosen in form screening to maximize the screening space of searching for all potential solid forms because some solvents selectively favor the generation of a particular form as a result of crystallization kinetics.

Roller Compaction is one of best processing methods to improve the flowability of API. Comparatively, direct compression which skips the granulation step is more cost- effective. Our enabling technique scan significantly improve the API particles flowability, make it possible to replace roller compaction process with direct compression process, and deliver quality products while simplifying the process.

Direct compression (DC) process is the preferred method for tablet production because it is both simple and energy saving.

Many active pharmaceutical ingredients (API) exhibit deficient bulk powder properties such as poor flowability, low bulk density, high cohesion, etc.

Many active pharmaceutical ingredients (API) exhibit deficient bulk powder properties such as poor flowability, low bulk density, high cohesion, etc.